- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Human immunodeficiency virus (HIV) infection
- Meeting Date: August 2019
- Public Summary Document (PSD) August 2019 PBAC Meeting - (PDF 706KB)
- Public Summary Document (PSD) August 2019 PBAC Meeting - (Word 181KB)
Dolutegravir with lamivudine – August 2019
DOLUTEGRAVIR with LAMIVUDINE, Tablet containing dolutegravir 50 mg (as sodium) with lamivudine 300 mg, Dovato®, ViiV Health Care Pty Ltd
Last updated
31 January 2020